Sentences with phrase «r myeloma patients»
Nearly 80 % of R / R myeloma patients with severe renal impairment requiring hemodialysis achieved disease control with this treatment combination.
http://www.cancernetwork.com/ Not exact matches
Speaking of checkpoint inhibitor drugs... Merck's star cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaths.
To participate in the study, which concludes in July 2020, patients must be 18 years or older and have a histological - or cytological - proven diagnosis of a malignancy in the lung, breast, head and neck, genitourinary organs or ovaries or multiple myeloma.
Empliciti will be used in combination with two other drugs to treat patients with multiple myeloma who have received one to three prior courses of medication.
The mission of the Multiple Myeloma Research Foundation (MMRF) is to accelerate next generation multiple myeloma treatments to extend patients» lives in pursuit of Myeloma Research Foundation (MMRF) is to accelerate next generation multiple myeloma treatments to extend patients» lives in pursuit of myeloma treatments to extend patients» lives in pursuit of a cure.
Whether one dollar or one thousand, your gift is helping LLS's mission to cure leukemia, lymphoma, Hodgkin's Disease, and myeloma as well as improve the quality of life of patients and their families.
The FDA approved Kyprolis for patients who have already been treated with at least two other multiple myeloma drugs, and Onyx is conducting other trials to win broader marketing approval.
«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Health.
To unravel exactly how ADAR1 is connected to disease severity at a molecular level, the researchers transferred multiple myeloma patient tissue to mice, creating what's known as a xenograft or «humanized» model.
Clinical trials that specifically test ADAR1 - targeted therapeutics for their safety and efficacy against multiple myeloma are still necessary before this approach could become available to patients.
«Despite new therapies, it's virtually inevitable that a patient with multiple myeloma will experience relapse of the disease at some point,» said senior author Catriona Jamieson, MD, PhD, professor of medicine, Koman Family Presidential Endowed Chair in Cancer Research and chief of the Division of Regenerative Medicine at UC San Diego School of Medicine.
Researchers used tissue and blood samples to show that the gammopathy (a precursor to myeloma) in both mice and patients with Gaucher disease is triggered by specific lipids, and that the antibodies made by tumor cells in nearly a third of myeloma patients are directed against such lipids.
Notably, the mechanism was clearly associated with poor outcome in patients with the blood cancer myeloma, where proteasome inhibitors are a mainstay of treatment.
Figure on the right: Bortezomib treatment is significantly less effective in multiple myeloma patients who have suppressed expression of a 19s proteasome cap subunit.
In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana - Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment - resistant forms of the disease.
Furthermore, the levels of Runx2 expression among a larger group of 351 newly diagnosed multiple myeloma patients were significantly higher in patients who had a high risk of early disease - related death, as compared with lower - risk patients.
«In summary, these encouraging data build upon the real success of our translational efforts in myeloma over the last decade, and provide exciting new options with the real promise of improving patient outcome,» said Richardson, who is also the R.J. Corman professor at Harvard Medical School.
But the relationship between multiple myeloma and the BMI of obese and morbidly obese patients was drastic.
«This suggests that Runx2 levels in myeloma cells may be a gene predictor of a patient's prognosis, good or bad,» Yang said.
In humans, a comparison of bone marrow from 14 normal bone marrow donors, 35 multiple myeloma patients and 11 patients with a noncancerous condition called monoclonal gammopathy of undetermined significance (MGUS) showed that Runx2 levels were significantly higher in the multiple myeloma cells.
Whether investigating fat cells, immunotherapy or use of the CRISPR - Cas 9 gene - editing tool, which a federal panel recently approved for a select number of patients suffering from three types of cancers, including multiple myeloma, approaches beyond attacking cancer cells are needed in the fight against many cancers.
The prognosis of myeloma patients with EMD behaves like other metastatic cancers and is extremely poor because its clinical course is very aggressive, Tse said.
«Based on our finding that being overweight or obese is a risk factor for multiple myeloma in MGUS patients, and since extra weight is a modifiable risk factor, we hope that our results will encourage intervention strategies to prevent the progression of this condition to multiple myeloma as soon as MGUS is diagnosed,» Chang said.
For this analysis, 605 patients with newly diagnosed multiple myeloma and treated with continuous lenalidomide (brand name Revlimid) following autologous stem cell transplant were compared to 604 patients who were treated with placebo or no maintenance.
«For patients diagnosed with MGUS, maintaining a healthy weight may be a way to prevent the progression to multiple myeloma, if further confirmed by clinical trials.»
«African - American multiple myeloma patients have higher incidence rates and lower survival rates than their Caucasian peers despite this being a relatively easy - to - treat cancer.
«There are clearly molecular differences between African - American and Caucasian multiple myeloma cases, and it will be critical to pursue these observations to better improve clinical management of the disease for all patients,» said John D. Carpten, senior author of the study and chair of the Department of Translational Genomics at the Keck School of Medicine.
And while 50 % of patients experienced a relapse of their myeloma, the subsequent treatment showed marked efficacy: 50 % of these patients were alive five years after the relapse.
Patients with multiple myeloma (MM) appear to have better survival if they are found to have monoclonal gammopathy of undetermined significance (MGUS) first, the state that precedes MM and which is typically diagnosed as part of a medical workup for another reason, according to a study published online by JAMA Oncology.
The authors speculate the reasons for the prolonged survival in their study is that patients with MGUS are evaluated more often for signs of progression to MM and may be diagnosed and started on therapy for myeloma at an earlier stage.
The method also is being evaluated in a clinical trial involving patients with multiple myeloma.
After being infused back into patients» bodies, these newly built cells both multiply and seek out a peptide expressed by the antigens NY - ESO - 1 and LAGE - 1 found in multiple myeloma cancer cells.
«And it has been instrumental in the prioritization of which experimental therapeutics should be tested in patients with multiple myeloma.»
One of the biggest questions about the treatment of multiple myeloma, a form of blood cancer, is why nearly all patients treated with current therapies eventually suffer relapse.
Although it is among the most highly metastatic of all cancers, multiple myeloma is driven to spread by only a subset of the myeloma cells within a patient's body, researchers at Dana - Farber Cancer Institute have found in a study presented at the annual meeting of the American Society of Hematology (ASH).
However, since MGUS and SMM are both asymptomatic conditions, most myeloma patients are not diagnosed until organ damage occurs.
«Despite current drugs and use of bone marrow transplantation, multiple myeloma is still incurable, and almost all patients eventually relapse,» says co-principal investigator and multiple myeloma specialist Craig Hofmeister, MD, MPH, assistant professor of medicine and a member of the OSUCCC — James Translational Therapeutics Program.
Dr Daniel Tennant, who led the research at the University of Birmingham, said, «Our findings show that very few changes are required for a MGUS patient to progress to myeloma as we now know virtually all patients with myeloma evolve from MGUS.
Dr Matt Kaiser, Head of Research at Bloodwise, said, «Myeloma is a devastating cancer that can cause debilitating and painful bone damage and, although we have become better at treating it and extending the lives of myeloma patients, it is ultimately almost alwaysMyeloma is a devastating cancer that can cause debilitating and painful bone damage and, although we have become better at treating it and extending the lives of myeloma patients, it is ultimately almost alwaysmyeloma patients, it is ultimately almost always fatal.
However, currently there is no way of accurately predicting which patients with MGUS are likely to go on to get myeloma.
As an organization of physicians and scientists who care for desperately ill patients, including those with blood cancers such as leukemia, lymphoma, and myeloma, the American Society of Hematology (ASH) is supportive of efforts to provide insurance parity for all approved evidence - based cancer treatments.
Multiple myeloma patients got some good news on November 16 — the immunotherapy daratumumab (Darzalex ®) was given approval by the FDA for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy.
Richard Vague, the event's honorary chair, took the podium to acknowledge the vast achievements of the ACC, as did Lori Alf, a multiple myeloma patient of Edward Stadtmauer, MD, chief of Hematologic Malignancies, whose cancer is in remission after receiving chimeric antigen receptor (CAR) therapy.
Plerixafor has been approved by the FDA as the first small - molecule CXCR4 antagonist for use in combination with granulocyte - colony stimulating factor (GCSF) to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
The only documented long - term complete remissions reported in multiple myeloma patients have occurred with allogeneic bone marrow transplantation, where a donor's blood stem cells (graft) are transplanted into the patient (host) with multiple myeloma.
Heidi Simmons decided to focus on cell therapy for treatment of blood cancers like leukemia, lymphoma and myeloma, where healthy cells are infused into patients to replenish those damaged by cancer.
As Director of the Hematologic Malignancies / Blood and Marrow Transplantation Program, Dr. Collins is proud that UT Southwestern offers the best care in the area for patients with leukemia, lymphoma, and myelomas.
Most multiple myeloma patients, however, are ineligible for allogeneic transplantation due to age and medical restrictions.
About one - half (45 %) of patients were enrolled in lymphoma trials, one - quarter (24 %) in chronic myeloid leukemia (CML) trials or multiple myeloma trials (22 %), and 2 % of patients were enrolled in trials of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
These patients were significantly underrepresented in trials of new treatments for lymphoma, CLL, and myeloma compared with the incidence of these diseases in that age group.